(Q48464565)

English

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis

scientific article published on 16 June 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17572882

0 references

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17572882

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

meta-regression

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

attention deficit hyperactivity disorder

1 reference

based on heuristic

inferred from title

author name string

Jackie Y W Cheng

1

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17572882

Ronald Y L Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17572882

John S N Ko

3

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17572882

Emil M L Ng

4

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17572882

publication date

16 June 2007

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17572882

number of pages

13

1 reference

based on heuristic

inferred from page(s)

Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17572882

194

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17572882

2

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17572882

197-209

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17572882

Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0840-X

21 January 2018

What's wrong with Bonferroni adjustments

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0840-X

21 January 2018

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0840-X

21 January 2018

Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Social impairment in girls with ADHD: patterns, gender comparisons, and correlates

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Severe liver injury after initiating therapy with atomoxetine in two children.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Obsessive compulsive disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Side effects of methylphenidate and desipramine alone and in combination in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discrimination of DSM-IV and latent class attention-deficit/hyperactivity disorder subtypes by educational and cognitive performance in a population-based sample of child and adolescent twins

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gender differences in ADHD: a meta-analysis and critical review

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response to methylphenidate in children with ADHD and comorbid anxiety

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine-induced hepatitis in a child.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ADHD comorbidity findings from the MTA study: comparing comorbid subgroups

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depressive disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Social functioning and emotional regulation in the attention deficit hyperactivity disorder subtypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential Effects of Methylphenidate on Working Memory in ADHD Children with and without Comorbid Anxiety

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind placebo controlled study of desipramine in the treatment of ADD: III. Lack of impact of comorbidity and family history factors on clinical response

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of anxiety on cognition, behavior, and stimulant response in ADHD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Psychiatric comorbidity and response to two doses of methylphenidate in children with attention deficit disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-007-0840-X

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17572882

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17572882

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48464565&oldid=2209493856"